Inflammation

Linkage of Cancer and Lupus in Gliomas Patients

Retrieved on: 
Monday, March 25, 2024
CD86, OS, TME, Gene, Transforming growth factor beta, CD68, Survival, LGG, Ligand, TGFB2, CD276, IDH, STAT1, Inflammation, Central nervous system, Patient, RNA, Tumor microenvironment, Cancer, Messenger, Macrophage, SLE, Expression, TAM, Treatment, Neoplasm, IRF5, Therapy, TGF, IRF1, TGFB, OTCQB, Demethylation, Vaccine

Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).

Key Points: 
  • Dr. Vuong Trieu, CEO and Chairman of Oncotelic, stated, ”Our R&D team has discovered crosstalk between the TGF-β and IFN signaling pathways, linking gliomas and Systemic Lupus Erythematosus (SLE).
  • Understanding the role of IRF5 in both SLE and cancer opens an avenue for targeting IRF5 or its downstream pathways.
  • LGG patients expressing high levels of TGFB2 and IFNGR2 are over-represented in IDH wild-type tumor samples, suggesting that TGFB2 and IFNGR2 mRNA can be therapeutically targeted in these high-risk patients.
  • Therefore, to improve OS in LGG patients, combination therapies must target TGFB2 and IFN-γ activation (via IRF5 inhibition) or immune therapies targeted against CD276/B7-H3

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Retrieved on: 
Monday, March 25, 2024
Research, Cancer Research UK, Biochemistry, Drug design, Partnership, Physician, Patient, SAN, MYCN, University, Cancer, Inflammation, TPD, Doctor of Philosophy, Therapy, Molecular biology, ALK, Pediatrics

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced that it is part of a diverse research team of international experts selected as awardees in this year’s Cancer Grand Challenges competition. The team includes scientists, physicians and patient advocacy groups from 10 institutions in the United States, the United Kingdom, France, Germany and Austria and will be led by Yael Mossé, M.D., Professor of Pediatrics and Patricia Brophy Endowed Chair in Neuroblastoma Research at the Children’s Hospital of Philadelphia, and Martin Eilers, Ph.D., Professor of Biochemistry and Molecular Biology at the University of Würzburg, Germany.

Key Points: 
  • The project entitled “Knocking Out Oncogenic Drivers and Curing Childhood Cancers” (KOODAC) has the goal of developing orally bioavailable targeted protein degraders that have the potential to dramatically improve cure rates for children affected by solid tumors.
  • "Team KOODAC brings together an interdisciplinary, international team of scientific experts, all sharing the vision of developing safe and effective drugs against previously undruggable childhood cancers," said Dr. Mossé.
  • This year, five teams were selected to receive funding of up to £20 million (approximately $25 million) over a period of five years.
  • The funds, which will support only the academic groups involved in the project, will be managed by Team KOODAC.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, March 24, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX

Retrieved on: 
Saturday, March 23, 2024
Prior, Psoriasis, Register, Form, District court, Defendant, News, Ext, LLP, IPO, Security (finance), Inflammation, Plaque, Prospectus, Complaint, File, Pomerantz, Action Replay, Court, Person

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.

Key Points: 
  • NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Retrieved on: 
Thursday, March 21, 2024
Glaucoma, B&L, Inflammation, Common, Telecanthus, NIH, CHRO, ISTA, Allergan, Pain, Therapy, Poultry farming

FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.

Key Points: 
  • FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it has formally launched its eye pain treatment program with the hiring of Dr. Simon Chandler.
  • The Company believes its sodium channel, NaV1.7 program will be suitable for an array of eye pain indications.
  • Common acute eye pain indications include corneal foreign body damage or abrasion, acute angle closure glaucoma and post-surgical sequelae.
  • “The launch of our eye pain treatment program represents a significant milestone for the Company.

Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease

Retrieved on: 
Thursday, March 21, 2024
EP4, Inflammation, Biomarker, IBD, Inflammatory bowel disease, Therapy, Safety, Pharmacokinetics, Pharmaceutical industry

This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.

Key Points: 
  • This approach is widely recognized to promote deeper remission and offer better long-term clinical outcomes1,2.
  • HTL’744 aims to address the significant unmet need of people with IBD that do not achieve satisfactory disease control.
  • The trial will be conducted in the UK and initial data read-outs are anticipated from 2025.
  • EP4 agonists are a recognized and exciting class of drugs with a dual mechanism of action that can resolve inflammation and promote mucosal healing.

Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Retrieved on: 
Wednesday, March 20, 2024
Zealand Pharma, Plasma, Rat, LC-MS/MS, Short bowel syndrome, Half-life, Inflammation, Patient, Tablet, Teduglutide, POC, OPKO Health, Injection, Entera, Pharmaceutical industry

The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.

Key Points: 
  • The program is focused on developing the first and only GLP-2 peptide tablet alternative for patients suffering from short bowel syndrome and additional disorders involving mucosal inflammation and nutrient malabsorption.
  • Currently, the only approved GLP-2 agonist, which is marketed under the name Gattex® (teduglutide), requires daily sub-cutaneous injections.
  • Entera and OPKO completed a proof of concept (PoC) single dose pharmacokinetic study in rodents as the first validation for oral administration of the GLP-2 treatment.
  • This data is consistent with previously reported PK data relating to OPKO’s GLP-2 peptide’s long acting profile, which had initially been developed as a weekly subcutaneous injection.

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Retrieved on: 
Wednesday, March 20, 2024
Cancer, Drug discovery, Patient, SAN, Inflammation, Poster, Biochemistry, Clinical trial, Therapy, Paclitaxel, Safety, ACS, American Chemical Society, Lymphoma, Pharmaceutical industry

SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA. This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.

Key Points: 
  • This is the first inhibitor of CBL-B to advance into clinical studies and a prime example of Nurix’s ability to target previously undruggable E3 ligases.
  • “Today’s presentation at the ACS meeting showcases Nurix’s innovative combination of structure-based-drug-design and industry-leading expertise in the biochemistry of E3 ligases,” noted Gwenn Hansen, Ph.D., Nurix’s chief scientific officer.
  • This mechanism of action is notable because CBL-B lacks a classic enzymatic active site binding pocket, preventing typical inhibitor design and thereby requiring a novel drug discovery approach.
  • A copy of the presentation is available on the Posters and Presentations section of the scientific resources page of Nurix’s website.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Children’s Place, and Ventyx and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, March 20, 2024
Psoriasis, Form, Defendant, News, IPO, Crohn's disease, Security (finance), Inflammation, Prospectus, P.C, File, Register

On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.

Key Points: 
  • On February 9, 2024, before the market opened, The Children’s Place announced its preliminary fourth quarter fiscal year 2023 financial results.
  • Therein, the Company revealed that it now expected fourth quarter net sales between $454 million and $456 million, falling short of previously issued guidance.
  • In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • As of the time this Complaint was filed, the price of Ventyx common stock continues to trade below the $16.00 per share Offering price, damaging investors.

Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Retrieved on: 
Tuesday, March 19, 2024
Cloud, OSA, APLS, ASRS, Environment, Patient, Public, Inflammation, News, LLP, Retinal scan, DOJ, Complaint, CMI, Retinal vasculitis, EPA, Justice, Society, Retina, Safety, Paratriathlon, Physician, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf of Cummins, Inc. against certain of its officers and directors.
  • Johnson Fistel LLP is investigating potential claims on behalf of Apellis Pharmaceuticals against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Inspire Medical Systems, Inc. against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Applied Digital Corporation against certain of its officers and directors.